Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Myovant Sciences stock | $22.83

Learn how to easily invest in Myovant Sciences stock.

Myovant Sciences Ltd is a biotechnology business based in the US. Myovant Sciences shares (MYOV) are listed on the NYSE and all prices are listed in US Dollars. Myovant Sciences employs 407 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Myovant Sciences

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MYOV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Myovant Sciences stock price (NYSE: MYOV)

Use our graph to track the performance of MYOV stocks over time.

Myovant Sciences shares at a glance

Information last updated 2021-09-12.
Latest market close$22.83
52-week range$13.42 - $29.71
50-day moving average $22.26
200-day moving average $21.63
Wall St. target price$31.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.13

Buy Myovant Sciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Myovant Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Myovant Sciences price performance over time

Historical closes compared with the close of $22.83 from 2021-09-17

1 week (2021-09-10) -6.89%
1 month (2021-08-18) 8.87%
3 months (2021-06-18) 8.46%
6 months (2021-03-18) -5.43%
1 year (2020-09-18) 3.82%
2 years (2019-09-18) 269.42%
3 years (2018-09-18) 24.99
5 years (2016-09-15) N/A

Myovant Sciences financials

Revenue TTM $67 million
Gross profit TTM $-79,361,000
Return on assets TTM -37.85%
Return on equity TTM 0%
Profit margin 0%
Book value $0.19
Market capitalisation $2.3 billion

TTM: trailing 12 months

Shorting Myovant Sciences shares

There are currently 5.1 million Myovant Sciences shares held short by investors – that's known as Myovant Sciences's "short interest". This figure is 29.2% up from 3.9 million last month.

There are a few different ways that this level of interest in shorting Myovant Sciences shares can be evaluated.

Myovant Sciences's "short interest ratio" (SIR)

Myovant Sciences's "short interest ratio" (SIR) is the quantity of Myovant Sciences shares currently shorted divided by the average quantity of Myovant Sciences shares traded daily (recently around 760248.58420268). Myovant Sciences's SIR currently stands at 6.71. In other words for every 100,000 Myovant Sciences shares traded daily on the market, roughly 6710 shares are currently held short.

However Myovant Sciences's short interest can also be evaluated against the total number of Myovant Sciences shares, or, against the total number of tradable Myovant Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Myovant Sciences's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Myovant Sciences shares in existence, roughly 60 shares are currently held short) or 0.1387% of the tradable shares (for every 100,000 tradable Myovant Sciences shares, roughly 139 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Myovant Sciences.

Find out more about how you can short Myovant Sciences stock.

Myovant Sciences share dividends

We're not expecting Myovant Sciences to pay a dividend over the next 12 months.

Myovant Sciences share price volatility

Over the last 12 months, Myovant Sciences's shares have ranged in value from as little as $13.42 up to $29.7083. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Myovant Sciences's is 2.8505. This would suggest that Myovant Sciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Myovant Sciences overview

Myovant Sciences Ltd. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction and is under phase 2 clinical trial. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health.

Frequently asked questions

What percentage of Myovant Sciences is owned by insiders or institutions?
Currently 60.208% of Myovant Sciences shares are held by insiders and 40.322% by institutions.
How many people work for Myovant Sciences?
Latest data suggests 407 work at Myovant Sciences.
When does the fiscal year end for Myovant Sciences?
Myovant Sciences's fiscal year ends in March.
Where is Myovant Sciences based?
Myovant Sciences's address is: 11-12 St. James?s Square, London, United Kingdom, SW1Y 4LB
What is Myovant Sciences's ISIN number?
Myovant Sciences's international securities identification number is: BMG637AM1024
What is Myovant Sciences's CUSIP number?
Myovant Sciences's Committee on Uniform Securities Identification Procedures number is: G637AM102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site